Search Results for "vol"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for vol. Results 61 to 70 of 400 total matches.

Cabtreo: A Three-Drug Gel for Acne

   
The Medical Letter on Drugs and Therapeutics • Apr 15, 2024  (Issue 1700)
(almost clear). The Medical Letter ® Vol. 66 (1700) April 15, 2024 60 Table 2. Some Topical Products ...
The FDA has approved Cabtreo (Bausch Health), a gel containing the retinoid adapalene, the oxidizing agent benzoyl peroxide, and the antibiotic clindamycin, for treatment of acne vulgaris in patients ≥12 years old. Cabtreo is the first three-drug topical formulation to become available in the US for treatment of acne.
Med Lett Drugs Ther. 2024 Apr 15;66(1700):59-60   doi:10.58347/tml.2024.1700b |  Show IntroductionHide Introduction

Gepirone (Exxua) for Depression

   
The Medical Letter on Drugs and Therapeutics • Jun 24, 2024  (Issue 1705)
and no significant effect on weight.7 The Medical Letter ® Vol. 66 (1705) June 24, 2024 Gepirone prolongs the QT ...
The FDA has approved an oral extended-release formulation of gepirone (Exxua – Fabre-Kramer), a selective 5-HT1A receptor agonist, for treatment of major depressive disorder (MDD) in adults. Gepirone was originally developed decades ago for treatment of anxiety and depression, but it was not approved by the FDA for such use. Gepirone is structurally related to buspirone, which is FDA-approved for treatment of anxiety.
Med Lett Drugs Ther. 2024 Jun 24;66(1705):97-9   doi:10.58347/tml.2024.1705a |  Show IntroductionHide Introduction

Donanemab (Kisunla) for Alzheimer's Disease

   
The Medical Letter on Drugs and Therapeutics • Aug 19, 2024  (Issue 1709)
of this material is strictly prohibited. For further information call: 800-211-2769 The Medical Letter ® Vol. 66 ...
Donanemab-azbt (Kisunla – Lilly), an IV amyloid beta-directed monoclonal antibody, has been approved by the FDA for treatment of Alzheimer's disease (AD). The label states that the drug should only be started in patients with mild cognitive impairment (MCI) or mild dementia. Donanemab is the third IV amyloid beta-directed monoclonal antibody to be marketed in the US. Lecanemab (Leqembi – Biogen/Eisai) was approved by the FDA in 2023 for the same indication as donanemab. Aducanumab (Aduhelm – Lilly) was granted accelerated approval in 2021, but it was withdrawn from the market...
Med Lett Drugs Ther. 2024 Aug 19;66(1709):129-31   doi:10.58347/tml.2024.1709a |  Show IntroductionHide Introduction

Ensifentrine (Ohtuvayre) for COPD

   
The Medical Letter on Drugs and Therapeutics • Aug 19, 2024  (Issue 1709)
The Medical Letter ® Vol. 66 (1709) August 19, 2024 132 69% of patients in ENHANCE-1 and 55% of those ...
The FDA has approved ensifentrine (Ohtuvayre – Verona), an inhaled phosphodiesterase (PDE) 3 and 4 inhibitor, for maintenance treatment of chronic obstructive pulmonary disease (COPD) in adults. It is the first dual inhibitor of PDE3 and PDE4 to be approved by the FDA, and the first inhaled drug with a new mechanism of action to be approved for treatment of COPD in more than 20 years.
Med Lett Drugs Ther. 2024 Aug 19;66(1709):131-3   doi:10.58347/tml.2024.1709b |  Show IntroductionHide Introduction

Risankizumab (Skyrizi) for Ulcerative Colitis

   
The Medical Letter on Drugs and Therapeutics • Nov 11, 2024  (Issue 1715)
: 260 mg; >55-85 kg: 390 mg; >85 kg: 520 mg. The Medical Letter ® Vol. 66 (1715) November 11, 2024 ...
The injectable interleukin (IL)-23 antagonist risankizumab-rzza (Skyrizi – Abbvie), previously approved by the FDA for treatment of Crohn's disease (CD), has now been approved for treatment of moderately to severely active ulcerative colitis (UC) in adults. Risankizumab is the first IL-23 antagonist to be approved for treatment of both CD and UC. It is also approved for treatment of plaque psoriasis and psoriatic arthritis.
Med Lett Drugs Ther. 2024 Nov 11;66(1715):182-4   doi:10.58347/tml.2024.1715d |  Show IntroductionHide Introduction

Capvaxive – A 21-Valent Pneumococcal Conjugate Vaccine

   
The Medical Letter on Drugs and Therapeutics • Oct 14, 2024  (Issue 1713)
. www.fdbhealth.com/drug-pricing-policy. The Medical Letter ® Vol. 66 (1713) October 14, 2024 162 Table 2 ...
The FDA has licensed Capvaxive (PCV21; Merck), a 21-valent pneumococcal conjugate vaccine, for prevention of invasive pneumococcal disease (IPD) and pneumococcal pneumonia in adults. Four other pneumococcal vaccines are currently available in the US: Prevnar 20 (PCV20), Vaxneuvance (PCV15), and Prevnar 13 (PCV13) are conjugate vaccines licensed for use in persons ≥6 weeks old, and Pneumovax 23 (PPSV23) is a pneumococcal polysaccharide vaccine licensed for use in persons ≥2 years old (see Table 1).
Med Lett Drugs Ther. 2024 Oct 14;66(1713):161-3   doi:10.58347/tml.2024.1713a |  Show IntroductionHide Introduction

Xanomeline/Trospium (Cobenfy) for Schizophrenia

   
The Medical Letter on Drugs and Therapeutics • Nov 11, 2024  (Issue 1715)
prohibited. For further information call: 800-211-2769 The Medical Letter ® Vol. 66 (1715) November 11 ...
The FDA has approved Cobenfy (BMS), an oral fixed-dose combination of the muscarinic agonist xanomeline and the peripheral muscarinic antagonist trospium chloride, for treatment of schizophrenia in adults. It is the first antipsychotic drug to be approved in the US for treatment of schizophrenia that does not block dopamine receptors. This is the first approval for xanomeline; trospium has been available for many years for treatment of overactive bladder.
Med Lett Drugs Ther. 2024 Nov 11;66(1715):177-9   doi:10.58347/tml.2024.1715a |  Show IntroductionHide Introduction

Drugs for Multiple Sclerosis

   
The Medical Letter on Drugs and Therapeutics • Mar 22, 2021  (Issue 1620)
to delay disease progression in patients with primary progressive MS. 43 The Medical Letter ® Vol. 63 ...
Most patients with multiple sclerosis (MS) present with the relapsing-remitting form of the disease. Pharmacologic treatment usually includes a disease-modifying drug, corticosteroids for acute exacerbations, and other drugs for managing symptoms such as fatigue, depression, and pain. Early use of disease-modifying therapy has improved clinical outcomes.
Med Lett Drugs Ther. 2021 Mar 22;63(1620):42-8 |  Show IntroductionHide Introduction

Nonopioid Drugs for Pain

   
The Medical Letter on Drugs and Therapeutics • Mar 07, 2022  (Issue 1645)
online The Medical Letter ® Vol. 64 (1645) March 7, 2022 34 Table 1. Some Nonopioid Analgesics ...
Nonopioid drugs can be used in the treatment of many nociceptive and neuropathic pain conditions. For severe pain, especially severe chronic cancer pain, use of opioids may be necessary. Noninvasive nonpharmacologic treatments, including physical and psychological therapies, have been shown to improve pain and function in patients with some common chronic pain conditions and are unlikely to cause serious harms. A multimodal approach to analgesic therapy can increase pain control while reducing opioid use and adverse effects.
Med Lett Drugs Ther. 2022 Mar 7;64(1645):33-40 |  Show IntroductionHide Introduction

Drugs and Devices for Weight Management

   
The Medical Letter on Drugs and Therapeutics • May 30, 2022  (Issue 1651)
........................................................................... online The Medical Letter ® Vol. 64 (1651) May 30, 2022 82 Table 1. Dosage and Cost of FDA-Approved ...
Adults with a body mass index (BMI) between 25 and 29.9 kg/m2 are considered overweight. Those with a BMI ≥30 are considered obese. The initial recommendation for any weight loss effort is to achieve a 5-10% reduction in weight, which has been associated with a reduction in the risk of developing type 2 diabetes, hypertension, and dyslipidemia. Diet, exercise, and behavior modification are the preferred methods for losing weight, but long-term weight maintenance can be difficult. Several drugs and devices are FDA-approved for weight reduction and maintenance of weight...
Med Lett Drugs Ther. 2022 May 30;64(1651):81-8 |  Show IntroductionHide Introduction